Preclinical CRO in
cancer research
Your partner for in vitro and in vivo services in oncology
ANTINEO SERVICES 2026
OUR VERSATILITY
Reactivity, adaptability and flexibility
OUR PERSONNALIZED ADVICE
An Advisory Board clinical expers to understand your needs and projects.
SECONDARY RESISTANCE MODELS
Established and characterized through RNAseq and immunophenotyping of the tumor microenvironment.
OUR COMPETITIVE PRICES
To provide our customers with excellent value for money
Our Strengths
Who we are
History
A spin-off of an academinc Team from the
Centre de Recherche en Cancérologie
( CRCL)
Expertise
10 years-old company
specialized in proof-of
concept studies in oncology
Track record
300+ studies
60+ sponsors
6 collaborative projects
150+ tumour models (syngeneic, PDX, xenografts) 30 models of secondary resistance 200 cell lines (90 human & equal syngeneic)
Antitumoral efficacy studies
Toxicity, MDT, PK studies
Original resistant models
Immunophenotyping
Up to 5 lasers and 29-markers panels Off the shelf or customized panels
Bioluminescence imaging
Antitimoral efficacy studies
Determinationof IC50 / EC50
Continuous-monitorig studies
Immune cells activation
ADCC and ADCP assays
T cell activation by iFNy measurements
Flow cytometry analysis
Up to 5 lasers and 29-markers panels
Off the shelf or customized panels
Splenocytes activation
3D Bioprinting
ADCC assays with fresh NK cells
In vitro services
Ensures precise extrusion bioprinting of standardized tumors models, enhancing reproducibility.
CELL VIABILITY
Assessing live cell populations
in tumor models.
PROLIFERATION
Monitoring growth rates of various cell types.
DRUG SENSITIVITY
Analyzing responses to
targeted therapeutic agents.
multicellurar models
Creating complex environments
for occurate testing.
Client Testimonial
« We have really benefited from Antineo expertise in preclinical services which has allowed us to establish proof of concept in xenograft models that they have identified, in-licensed and developed for us. Project management is very professionally done with regular reporting in a proactive mode. It is really nice to work with the whole team ! »
— Cécile Bougeret, Vice President of Operations, Evextabio
Set up an appointment
They trust us : Pulsalys | Roche | Université de Tours | CRCL
2026 Antineo – Tous droits réservés | antineo.fr